# To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer

> **NCT03792074** · PHASE3 · UNKNOWN · sponsor: **Sinocelltech Ltd.** · enrollment: 560 (estimated)

## Conditions studied

- Non-squamous Cell Non-small Cell Lung Cancer

## Interventions

- **DRUG:** SCT510
- **DRUG:** Bevacizumab
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT03792074
- **Lead sponsor:** Sinocelltech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-02
- **Primary completion:** 2021-05
- **Final completion:** 2022-01
- **Target enrollment:** 560 (ESTIMATED)
- **Last updated:** 2019-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03792074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03792074, "To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03792074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*